Patient choice and the effectiveness and safety of HIFU

An interesting article has just been published in the Journal of Urology which helps to provide information (and context) about the quality of data supporting the use of high-intensity focused ultrasound (HIFU) in the treatment of prostate cancer. … READ MORE …

Brachy boost therapy should be reserved for unfavorable risk patients

The ASCENDE-RT trial showed that oncological outcomes were improved among both intermediate-risk and high-risk men who were treated with external beam radiation (EBRT) and a brachytherapy boost (LDR-BT) to the prostate and adjuvant androgen deprivation therapy (ADT) (see this link). … READ MORE …

SBRT dose escalation

Is there an optimum treatment dose for sterotactic body radiation therapy (SBRT)? … READ MORE …

No need to endure 38 to 44 treatments with IMRT anymore

There have been several hypofractionation trials maturing in the last couple of years. With minor exceptions, they all tell the same story: external beam radiation therapy (EBRT) can be completed in less time without loss of efficacy or increase in toxicity. … READ MORE …

Decision making and the treatment of localized prostate cancer today

This month’s issue of Urologic Oncology contains a series of six articles that may be of particular interest to prostate cancer support group leaders and other prostate cancer educators. … READ MORE …

Effective, safe, and as fast as reasonably possible

For readers who are interested in the processes and the speed with which potential new cancer drugs can be brought to market here in the USA (and other places around the world too), there in an important article in this week’s New England Journal of Medicine. … READ MORE …

Prostate cancer screening said to be “not cost effective”

A new review article in Future Oncology has suggested that

even when based on favorable randomized controlled trials in younger age groups, prostate cancer screening is still not cost effective.

… READ MORE …